PE20200340A1 - Compuestos heteroaromaticos como inhibidores de vanina - Google Patents
Compuestos heteroaromaticos como inhibidores de vaninaInfo
- Publication number
- PE20200340A1 PE20200340A1 PE2019002531A PE2019002531A PE20200340A1 PE 20200340 A1 PE20200340 A1 PE 20200340A1 PE 2019002531 A PE2019002531 A PE 2019002531A PE 2019002531 A PE2019002531 A PE 2019002531A PE 20200340 A1 PE20200340 A1 PE 20200340A1
- Authority
- PE
- Peru
- Prior art keywords
- heteroaromatic compounds
- alkyl
- vanin
- compound
- formula
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000002390 heteroarenes Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Referido a un compuesto de formula I; en donde A es un grupo de formula A.1 o A.2, en donde cada R1, R2, R3, R4, R5 y R6 son independientemente H, C1-C4 alquilo, entre otros; y B se selecciona del grupo B1, B.2 y B3, en donde R7 es H, C1-3-alquilo, halogeno, entre otros; R8 es C1-C6-alquilo, C3-C6-cicloalquilo, entre otros. Este compuesto es un inhibidor de vanina, siendo util en el tratamiento de enfermedades como enfermedad de Crohn y colitis ulcerosa. Tambien se refiere a procesos para la produccion de dichos compuestos y preparaciones farmaceuticas que los contienen.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762518106P | 2017-06-12 | 2017-06-12 | |
| PCT/EP2018/065140 WO2018228934A1 (en) | 2017-06-12 | 2018-06-08 | Heteroaromatic compounds as vanin inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20200340A1 true PE20200340A1 (es) | 2020-02-14 |
Family
ID=62631060
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2019002531A PE20200340A1 (es) | 2017-06-12 | 2018-06-08 | Compuestos heteroaromaticos como inhibidores de vanina |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US10364255B2 (es) |
| EP (1) | EP3638680B1 (es) |
| JP (1) | JP6880243B2 (es) |
| KR (1) | KR102607934B1 (es) |
| CN (1) | CN110770242B (es) |
| AR (1) | AR112086A1 (es) |
| AU (1) | AU2018285131B2 (es) |
| CA (1) | CA3066946A1 (es) |
| CL (1) | CL2019003515A1 (es) |
| CO (1) | CO2019013823A2 (es) |
| DK (1) | DK3638680T3 (es) |
| EA (1) | EA039223B1 (es) |
| ES (1) | ES2927021T3 (es) |
| HU (1) | HUE060597T2 (es) |
| IL (1) | IL271104B (es) |
| MA (1) | MA49374A (es) |
| MX (1) | MX394645B (es) |
| PE (1) | PE20200340A1 (es) |
| PH (1) | PH12019502693A1 (es) |
| PL (1) | PL3638680T3 (es) |
| TW (1) | TWI855993B (es) |
| WO (1) | WO2018228934A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| EA039223B1 (ru) * | 2017-06-12 | 2021-12-20 | Бёрингер Ингельхайм Интернациональ Гмбх | Гетероароматические соединения в качестве ингибиторов ванина |
| JP7637049B2 (ja) | 2018-08-13 | 2025-02-27 | エフ． ホフマン－ラ ロシュ アーゲー | モノアシルグリセロールリパーゼ阻害剤としての新規の複素環化合物 |
| AU2019326933B2 (en) | 2018-08-28 | 2024-12-05 | Boehringer Ingelheim International Gmbh | Heteroaromatic compounds as Vanin inhibitors |
| CA3120037A1 (en) | 2018-12-03 | 2020-06-11 | Boehringer Ingelheim International Gmbh | Heteroaromatic compounds as vanin inhibitors |
| HUE060872T2 (hu) | 2018-12-03 | 2023-04-28 | Boehringer Ingelheim Int | Heteroaromás vegyületek mint vanin-inhibitorok |
| TWI838430B (zh) | 2018-12-03 | 2024-04-11 | 德商百靈佳殷格翰國際股份有限公司 | 作為vanin抑制劑之雜芳族化合物 |
| CA3151516A1 (en) | 2019-09-12 | 2021-03-18 | F. Hoffmann-La Roche Ag | 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors |
| US20230107927A1 (en) | 2020-02-28 | 2023-04-06 | First Wave Bio, Inc. | Methods of treating iatrogenic autoimmune colitis |
| WO2024212017A1 (es) | 2023-04-10 | 2024-10-17 | UMOV SpA | Sistema de rehabilitación y monitoreo |
| CN118892548A (zh) * | 2024-08-12 | 2024-11-05 | 中国人民解放军陆军特色医学中心 | Vanin-1抑制剂在制备治疗急性肾损伤继发急性肺损伤的药物中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2540868A1 (en) * | 2003-10-09 | 2005-04-21 | Abbott Laboratories | Pyrrolidinyl urea derivatives as angiogenesis inhibitors |
| CA2987179C (en) * | 2015-05-29 | 2020-08-25 | Pfizer Inc. | Heterocyclic compounds as inhibitors of vanin-1 enzyme |
| AU2017296338A1 (en) * | 2016-07-14 | 2019-01-03 | Pfizer Inc. | Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme |
| EA039223B1 (ru) * | 2017-06-12 | 2021-12-20 | Бёрингер Ингельхайм Интернациональ Гмбх | Гетероароматические соединения в качестве ингибиторов ванина |
-
2018
- 2018-06-08 EA EA202090014A patent/EA039223B1/ru unknown
- 2018-06-08 WO PCT/EP2018/065140 patent/WO2018228934A1/en not_active Ceased
- 2018-06-08 ES ES18731766T patent/ES2927021T3/es active Active
- 2018-06-08 JP JP2019566724A patent/JP6880243B2/ja active Active
- 2018-06-08 PE PE2019002531A patent/PE20200340A1/es unknown
- 2018-06-08 CN CN201880039562.3A patent/CN110770242B/zh active Active
- 2018-06-08 KR KR1020197038628A patent/KR102607934B1/ko active Active
- 2018-06-08 AU AU2018285131A patent/AU2018285131B2/en active Active
- 2018-06-08 CA CA3066946A patent/CA3066946A1/en active Pending
- 2018-06-08 HU HUE18731766A patent/HUE060597T2/hu unknown
- 2018-06-08 US US16/003,252 patent/US10364255B2/en active Active
- 2018-06-08 EP EP18731766.4A patent/EP3638680B1/en active Active
- 2018-06-08 MX MX2019014876A patent/MX394645B/es unknown
- 2018-06-08 PL PL18731766.4T patent/PL3638680T3/pl unknown
- 2018-06-08 MA MA049374A patent/MA49374A/fr unknown
- 2018-06-08 DK DK18731766.4T patent/DK3638680T3/da active
- 2018-06-11 AR ARP180101573A patent/AR112086A1/es unknown
- 2018-06-11 TW TW107119946A patent/TWI855993B/zh active
-
2019
- 2019-05-13 US US16/410,037 patent/US20190263828A1/en not_active Abandoned
- 2019-11-28 PH PH12019502693A patent/PH12019502693A1/en unknown
- 2019-12-02 CL CL2019003515A patent/CL2019003515A1/es unknown
- 2019-12-02 IL IL271104A patent/IL271104B/en unknown
- 2019-12-09 CO CONC2019/0013823A patent/CO2019013823A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA039223B1 (ru) | 2021-12-20 |
| HUE060597T2 (hu) | 2023-04-28 |
| TWI855993B (zh) | 2024-09-21 |
| JP2020522517A (ja) | 2020-07-30 |
| US10364255B2 (en) | 2019-07-30 |
| MX2019014876A (es) | 2020-02-13 |
| CL2019003515A1 (es) | 2020-06-19 |
| BR112019021703A2 (pt) | 2020-05-12 |
| US20180354968A1 (en) | 2018-12-13 |
| US20190263828A1 (en) | 2019-08-29 |
| EA202090014A1 (ru) | 2020-05-12 |
| TW201920196A (zh) | 2019-06-01 |
| IL271104A (en) | 2020-01-30 |
| MX394645B (es) | 2025-03-21 |
| CA3066946A1 (en) | 2018-12-20 |
| AU2018285131B2 (en) | 2021-11-11 |
| WO2018228934A1 (en) | 2018-12-20 |
| EP3638680A1 (en) | 2020-04-22 |
| CN110770242B (zh) | 2022-08-19 |
| DK3638680T3 (da) | 2022-09-05 |
| AU2018285131A1 (en) | 2019-10-31 |
| KR102607934B1 (ko) | 2023-12-01 |
| JP6880243B2 (ja) | 2021-06-02 |
| ES2927021T3 (es) | 2022-11-02 |
| CO2019013823A2 (es) | 2020-01-17 |
| PL3638680T3 (pl) | 2022-12-19 |
| CN110770242A (zh) | 2020-02-07 |
| IL271104B (en) | 2022-03-01 |
| MA49374A (fr) | 2021-04-21 |
| EP3638680B1 (en) | 2022-08-10 |
| KR20200013718A (ko) | 2020-02-07 |
| PH12019502693A1 (en) | 2020-07-13 |
| AR112086A1 (es) | 2019-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20200340A1 (es) | Compuestos heteroaromaticos como inhibidores de vanina | |
| AR114164A1 (es) | Piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1 | |
| CY1123595T1 (el) | Παραγωγα χολικου οξεος ως αγωνιστες fxr/tgr5 | |
| CL2018000338A1 (es) | Derivados de heteroarilo como inhiidores de parp | |
| PE20181298A1 (es) | Inhibidores de bromodominio bivalentes y usos de los mismos | |
| ECSP19051409A (es) | Nuevo compuesto heterocíclico, su método de preparación y composición farmacéutica que lo comprende | |
| CL2019000512A1 (es) | Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infección vírica. | |
| PE20180024A1 (es) | Triazolopirazinonas como inhibidores de pde1 | |
| MX2020001757A (es) | Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades. | |
| PE20161225A1 (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| BR112017003054A2 (pt) | compostos de aminopirimidinila como inibidores de jak | |
| DOP2016000208A (es) | Benzimidazol-2-aminas como inhibidores de midh1 | |
| NI201700029A (es) | Compuestos y composiciones como inhibidores de quinasa raf. | |
| MX2016012145A (es) | Composicion de control de enfermedades de plantas y metodo para controlar enfermedades de plantas mediante su aplicacion. | |
| JOP20210030A1 (ar) | مثبطات تفاعل البروتين-بروتين KEAP1-Nrf2 | |
| CL2019000476A1 (es) | Compuestos de heteroarilcarboxamida como inhibidores de ripk2. | |
| EA201891644A1 (ru) | Антибактериальные соединения и их применение | |
| EA201790745A1 (ru) | Трициклические соединения | |
| CO2019004978A2 (es) | Compuestos terapéuticos y métodos para utilizarlos | |
| TR201900148T4 (tr) | Kansere karşı yeni maddeler olarak sübstitüe edilmiş 2,4 diamino-kinolin. | |
| PE20181017A1 (es) | Compuestos heteroarilo y su uso como farmacos terapeuticos | |
| AR101290A1 (es) | Inhibidores de aldosterona sintasa | |
| CU20160166A7 (es) | Compuestos derivados de n-(1,5-dimetil-3-oxo-2,3-dihidro-1h-pirazol-4-il)-4-metil-5-isoxazol-3-carboxamida activos como inhibidores selectivos de smurf-1 | |
| CO2017000011A2 (es) | Derivados de quinolizinona como inhibidores de pi3k | |
| PH12016502568B1 (en) | Novel heterocyclic compound |